glp-1 bone loss Do Drugs Cause Loss? New Research on Osteoporosis Risk AAOS: GLP-1 receptor agonist use

Receptor subtype-selective binding and functional assays typically comparing synephrine's potency at beta-1, beta-2, and beta-3 adrenergic receptor subtypes using cAMP accumulation or radioligand displacement methods are used to characterise its relative selectivity profile

10.1016/j.abb.2023.109691 99 LiuS.GaoX.ZhouS

doi: 10.14348/molcells.2019.0196 134 KrauzovEKramerovJRossmeislovLMaliovLTencerovMKocMet al

The contrarian point is that the GLP-1 patient is not a lost gym customer but the most pre-qualified one in the industry, because the drug strips muscle along with fat and the only way to keep that muscle is strength training